Comparison of immunoadjuvant activities of four bursal peptides combined with H9N2 avian influenza virus vaccine
2018
Cong Zhang, Henan University of Science and Technology, Luoyang, China | Jiangfei Zhou, Henan University of Science and Technology, Luoyang, China | Zhixin Liu, Henan University of Science and Technology, Luoyang, China | Yongqing Liu, Henan University of Science and Technology, Luoyang, China | Kairui Cai, Henan University of Science and Technology, Luoyang, China | Tengfei Shen, Henan University of Science and Technology, Luoyang, China | Chengshui Liao, Henan University of Science and Technology, Luoyang, China | Chen Wang, Henan University of Science and Technology, Luoyang, China
The bursa of Fabricius (BF) is a central humoral immune organ unique to birds. Four bursal peptides (BP-I, BP-II, BP-III, and BP-IV) have been isolated and identified from the BF. In this study, the immunoadjuvant activities of BPs I to IV were examined in mice immunized with H9N2 avian influenza virus (AIV) vaccine. The results suggested that BP-I effectively enhanced cell-mediated immune responses, increased the secretion of Th1 (interferon gamma)- and Th2 (interleukin-4)-type cytokines, and induced an improved cytotoxic T-lymphocyte (CTL) response to the H9N2 virus. BP-II mainly elevated specific antibody production, especially neutralizing antibodies, and increased Th1- and Th2-type cytokine secretion. BP-III had no significant effect on antibody production or cell-mediated immune responses compared to those in the control group. A strong immune response at both the humoral and cellular levels was induced by BP-IV. Furthermore, a virus challenge experiment followed by H and E staining revealed that BP-I and BP-II promoted removal of the virus and conferred protection in mouse lungs. BP-IV significantly reduced viral titers and histopathological changes and contributed to protection against H9N2 AIV challenge in mouse lungs. This study further elucidated the immunoadjuvant activities of BPs I to IV, providing a novel insight into immunoadjuvants for use in vaccine design.
显示更多 [+] 显示较少 [-]